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Spindle damage responsebreast cancer susceptibility gene 1 (BRCA1) confer an increased risk for breast,
ovarian and prostate cancer. BRCA1 has been involved in regulation of cell cycle progression, DNA damage
signaling and repair, maintenance of genome integrity, ubiquitination and regulation of transcription. Aside
from its essential functions in the DNA damage response BRCA1 has been also involved in the cellular
response to microtubule damage. Emerging evidence indicates that BRCA1 regulates the duplication and the
function of centrosomes, participates in mitotic spindle assembly and is required in the spindle checkpoint.
Given BRCA1 distinct functions in microtubule-dependent pathways, we hypothesized that BRCA1 might be
regulated following microtubule damage. In the present study, we report the novel ﬁnding that BRCA1 is
phosphorylated by the checkpoint kinase Chk2 on the previously identiﬁed site Ser988 following anti-mitotic
treatment in human cancer cells. Ser988-phosphorylated BRCA1 accumulates at centrosomes in response to
microtubule damage but Ser988 is not essential for BRCA1 localization at the microtubule-organizing centers.
We further demonstrate that the Ser988 phosphorylation is important for the inhibiting microtubule
nucleation activity of BRCA1 and for BRCA1 function in cell survival following microtubule damage. These
ﬁndings reveal a striking outcome of BRCA1 phosphorylation by Chk2 on its role in microtubule-dependent
pathways and suggest a ﬁne cross-talk between DNA damage and spindle damage responses.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Inherited mutations of the breast cancer susceptibility gene 1
(BRCA1) confer an increased risk for breast, ovarian and prostate
cancer [1,2]. In addition, absent or reduced BRCA1 expression due to
promoter methylation is commonly observed in sporadic breast and
ovarian cancer, also implicating BRCA1 in non hereditary tumors [3,4].
Established functional roles of BRCA1 include regulation of cell cycle
progression, DNA damage signaling and repair, maintenance of
genome integrity, ubiquitination and regulation of transcription [5].
However, the speciﬁc functions of the BRCA1 protein that contribute
to tumor suppression remain to be deﬁned.
Following exposure to various genotoxic stimuli, BRCA1 is highly
regulated through phosphorylations, predominantly on serine residues
[6]. Several kinases have been shown to phosphorylate BRCA1 on
speciﬁc residues under conditions of DNA damage, such as the protein
kinases ATM and ATR [7,8]. In response to ionizing radiations (IR), ATM
phosphorylates and activates another checkpoint kinase, Chk2, which
in turn can phosphorylate BRCA1 on Ser988 [9]. Phosphorylation on
Ser988 has been shown to be necessary for the BRCA1 protein to
mediate survival after DNA damage in a BRCA1-mutated cell line [9].
Recently, the biological consequences entailed by BRCA1 phosphoryla-
tion on Ser988 following exposure to IR was shown to be essential forl rights reserved.the role of BRCA1 in the repair of double-strand breaks (DSBs) by
promoting error-free homologous recombination (HR) and by
inhibiting the error-prone microhomology-mediated subpathway of
nonhomologous end-joining (NHEJ) [10–12]. Interesting results were
obtained from knock-in mice that carry the Ser to Ala mutation of
Ser971 ofmouse BRCA1, which is equivalent to Ser988 of humanBRCA1
[13]. Mice homozygous for BRCA1 S971A were viable without any
developmental deﬁciency, but develop uterus hyperplasia and
abnormality of the ovary. When irradiated with IR, they exhibited
lymphoma, mammary and endometrial tumors, suggesting that BRCA1
phosphorylation on Ser971 plays a crucial role in repressing cell
transformation [13].
Aside from its essential functions in the DNA damage response,
BRCA1 has been also involved in the cellular response to microtubule
damage. Indeed, BRCA1 deﬁciency confers resistance to anti-
microtubule agents, such as paclitaxel (Taxol®) and Vinorelbine
[14–17], that disrupt the mitotic spindle assembly and lead to
activation of a surveillance mechanism known as the spindle
checkpoint at the metaphase–anaphase transition [18]. As one key
function of BRCA1 in the spindle damage response, we and others
have recently showed that BRCA1 is involved in the control of the
spindle assembly checkpoint in human cells [17] and in mouse cells
[19], emphasizing a new function of BRCA1 in mitosis. The spindle
checkpoint monitors both the attachment of the chromosomes to the
mitotic spindle and the tension across the sister-chromatids
generated by microtubules to prevent premature sister-chromatids
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spindle checkpoint include Mad1, Mad2, Bub1, BubR1, Bub3 and
Mps1, that inhibit the activity of the anaphase-promoting complex
(APC/C), inducing a delay in the onset of anaphase [21,22]. BRCA1
regulates the spindle checkpoint, at least in part, through the
transcriptional activation of BubR1 [17,23] and of Mad2 [19].
In addition to its multiple nuclear functions, BRCA1 plays also a
role in maintaining the centrosome number in mammary cells [24,
25]. It localizes throughout the cell cycle to centrosome, the major
microtubule-organizing center in mammalian cells [26] and binds
to γ-tubulin, a centrosomal component that nucleates the
microtubules as part of the γ-tubulin ring complex [27,28]. It was
recently shown that the BRCA1-dependent ubiquitination directed
at γ-tubulin inhibits microtubule nucleation by the centrosome in
breast cancer cells [26]. These ﬁndings suggest that loss of BRCA1
could cause centrosome abnormalities, resulting in aneuploidy in
breast tumors.
Given the new physiological functions of BRCA1 in the control of
the spindle checkpoint and in the centrosomal microtubule nuclea-
tion, we hypothesized that BRCA1 might function as a sensor of
microtubule damage induced by anti-mitotic drugs and that it may be
regulated following microtubule damage. Studies of BRCA1
phosphorylations have, for the most part, explored the DNA damage
pathway. Thus, it remains to be determined whether BRCA1 is
phosphorylated following other types of stress, such as the one
induced by microtubule-interfering agents. In the present study, we
report the novel ﬁnding that BRCA1 is phosphorylated by Chk2 on the
previously identiﬁed Ser988 site following spindle damage and
accumulates at centrosome. Our results show that anti-microtubule
treatment induces changes in Chk2 phosphorylation state, suggesting
potential involvement of Chk2 in the spindle damage response. We
further demonstrate that the Ser988 site is necessary for the inhibiting
microtubule nucleation activity of BRCA1 and is important for BRCA1
function in cell survival followingmicrotubule damage. These ﬁndings
reveal a striking outcome of BRCA1 phosphorylation on its role in
spindle damage response.
2. Materials and methods
2.1. Cell lines and treatment
MCF-7, HeLa and HCC1937 cancer cell lines were obtained from the
American Type Culture Collection (Rockville, MD). Parental HCT116
colon cancer cells and HCT116 lacking Chk2 were kindly provided by
Dr B. Vogelstein (John Hopkins Kimmel Cancer Center, Baltimore, MD,
USA). Targeted deletion of the human Chk2 locus in HCT116 cells was
obtained through homologous recombination [29]. HCC1937 cell line
was established from a primary breast carcinoma and weakly
expresses a COOH-terminal truncated BRCA1 protein that is unstable
and not functional [30]. MCF-7 cells were grown in RPMI-1640
medium with L-glutamine supplemented with 5% fetal calf serum,
50 μg/mL gentamycin and 1 μM insulin. HeLa, HCT116 and HCC1937
cells were grown in ATCC recommended medium. When indicated,
cells were treated with various concentrations of paclitaxel (PTX)
(Sigma), 10 mM hydroxyurea (HU) (Sigma) or 200 ng/mL nocodazole
(NOC) (Sigma) for the indicated time periods.
2.2. Western blot analysis
Whole-cell extracts were prepared and immunoblots were
performed as previously described [17]. The primary antibodies used
to detect proteins were monoclonal anti-BRCA1 Ab-1 (1:50,
Calbiochem), monoclonal anti-HSP60 (1:1000, Sigma), monoclonal
anti-HA (1:1000, Babco), polyclonal goat anti-pBRCA1 S988 (1:100,
Santa Cruz), monoclonal anti-Chk2 B-4 (1:200, Santa Cruz) and
polyclonal rabbit anti-pChk2 Thr68 (1:100, Abcam) antibodies.2.3. Mitotic cells collection
Mitotic cells were collected by shake-off over a period of 48 h.
Mitotic index was determined by ﬂow cytometry on ethanol-ﬁxed
cells incubated with polyclonal anti-phosphorylated histone H3
antibody (1:150, Upstate). After washing in PBS-1% BSA, cells were
stained with Alexa488-anti-Rabbit IgG antibody (1:800, Interchim)
and propidium iodide (10 μg/mL, Sigma) in presence of 1 mg/mL
RNAse A (Sigma) and loaded onto the FACSCalibur (Becton Dickinson).
Cell cycle proﬁles were analyzed using ModFit and CellQuest
softwares (Becton Dickinson).
2.4. Immunoprecipitation
Following transient transfection and/or drug treatment, MCF-7
cells were harvested and lysed as previously described [17]. 500 μg of
whole-cell extracts were incubated with 10 μg of rabbit polyclonal
anti-BRCA1 antibody (BD Biosciences) or with 2 μg of rabbit polyclonal
HA-probe Y-11 (Santa Cruz) at 4 °C overnight. Immune complexes
were recovered with protein A-sepharose beads (Pharmacia) and
washed three times using lysis buffer. Then beads were subjected to
Western Blot analysis. Control immunoprecipitation was performed
using a non-relevant rabbit IgG fraction.
2.5. Small-interfering RNA (siRNA) Knockdown of BRCA1 and Chk2
siRNA sequence pools directed against BRCA1 (Smartpool®
containing four pooled siRNA duplexes, Dharmacon) and siRNA
duplex directed against Chk2 (5′GAACCUGAGGACCAAGAAC3′, Euro-
gentec) were used previously [17,31]. Transfection was performed
with 100 nM of the indicated siRNA duplexes using Lipofectamine
2000 (Invitrogen). For control experiments, cells were transfected
with scrambled siRNA duplex 5′UCACAGUGUCCUUUAUGUA-3′
(Dharmacon).
2.6. Phosphatase assay
50 μg of whole-cell extracts prepared without phosphatase
inhibitors were incubated in λ protein phosphatase buffer (Biolabs)
containing 100 U of λ protein phosphatase (Biolabs) for 1 h at 37 °C.
Enzymatic reactions were stopped by adding Laemmli buffer and by
incubating samples at 95 °C for 5 min.
2.7. Plasmid transfection
Transient transfection of pcDNA3 vectors encoding HA-tagged wt
BRCA1 or HA-tagged BRCA1 (S988A) was performed with Lipofectin
Reagent®(Invitrogen) using the manufacturer's recommendations.
Plasmids were a generous gift from Dr J.H. Chung (NHLBI, NIH,
Bethesda, USA). For control experiments, cells were transfected with
empty pcDNA3-HA vector.
2.8. Immunoﬂuorescence microscopy
Cells grown on glass coverslips were treated with paclitaxel or
nocodazole 24 h following siRNA or plasmid transfection. For pSer988
BRCA1 staining, cells were ﬁxed in formaldehyde 3.7% for 20 min,
permeabilized in 0.5% Triton X-100 for 5 min on ice and incubated in
methanol for 20min at −20 °C.When required, cells were incubated in
λ protein phosphatase buffer containing 200 U of λ protein
phosphatase (Biolabs) for 1 h at 37 °C following methanol incubation.
For HA or BRCA1 staining, cells were pre-permeabilized with 0.02%
saponin, ﬁxed in formaldehyde 3.7% for 20 min and incubated in
methanol for 20 min at −20°C. Then cells were incubated in blocking
solution (3% BSA, 0.3% Triton X-100) for 30 min and stained with
polyclonal anti-pBRCA1 S988 (1:100), monoclonal anti-BRCA1 D9
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temperature. After washes with PBS, incubation with the ﬁrst
secondary antibody was performed in the same conditions with
Alexa 594-anti goat or Alexa 488 anti-mouse IgG (Interchim). Then
cells were stained with monoclonal or polyclonal anti-γ-tubulin
antibody (1:1000, Sigma) for 1 h followed by staining with secondary
antibody Alexa-488 anti-mouse or Alexa-594 anti-Rabbit IgG. Samples
were washed in PBS and then counterstained with DAPI (500 ng/mL).
Slides were mounted with ﬂuorescent mounting medium (Dako) and
examined using a ﬂuorescence microscope (Leica DM6000) under the
100× objective lens. Images were captured by a coolsnap Es digital
camera. When required, mitotic index was determined by DAPI
staining by scoring N1000 cells.
Quantiﬁcation of ﬂuorescence was performed using Metamorph
software. Images were captured with the same exposure time for a
similar wavelength. Centrosomal area in mitotic cells was delimited
owing to γ-tubulin staining (488 nm). Average intensity of
ﬂuorescence linked to pBRCA1 S988 (594 nm) was quantiﬁed in this
γ-tubulin area. Histograms show mean values obtained from at least
50 cells analyzed from two independent experiments.
Analysis of centrosomal localization of HA-tagged BRCA1 was
performed on z-stack images. 11 images were captured each 0.2 μm
and centrosomal localization of BRCA1 was examined in each stack
owing to γ-tubulin staining. Percentage of cells with centrosomal
localization of HA-tagged BRCA1 was determined by scoring N150Fig. 1. BRCA1 is phosphorylated on Serine 988 upon spindle damage. (A) BRCA1 phosphoryla
treated with 100 nM paclitaxel at time 0 h and harvested at the indicated time-points. Cel
antibodies.Mitotic indexwas scored usingDAPI staining. (B) BRCA1 is phosphorylated on Serin
24 h after incubation with 100 nM paclitaxel (PTX), 200 ng/mL nocodazole (NOC) or 10 mM
immunoblot analysis using anti-pBRCA1 S988 and anti-BRCA1 antibodies. Anti-HSP60 anti
exponentially growing cells. (C) Phosphorylation of BRCA1 on Ser988 is not induced by M ph
protein immunoblot analysis using anti-pBRCA1 S988 and anti-HSP60 antibodies. Mitotic ind
growing cells. (D–F) Target speciﬁcity of the anti-pBRCA1 S988 antibody. (D) Twenty-four hour
cellswere treatedwith 100nMPTX for 24h and thenwereharvested and lysed. (E)When indica
tagged wtBRCA1 or HA-tagged BRCA1 S988A, MCF-7 cells were treated with 100 nM PT
immunoprecipitate HA-BRCA1 using 2 μg of rabbit anti-HA antibody. Immunoblot analysis wtransfectants from 3 independent experiments. Percentage of cells
with centrosomal localization of BRCA1 following Chk2 down-
regulation was obtained by scoring ≥100 cells per condition from 2
independent experiments.
2.9. Microtubule regrowth assay
24 h following transfection with plasmids, cells grown on glass
coverslips were treated with 10 μg/mL nocodazole-containing cold
medium for 1 h on ice. Microtubules were allowed to regrow in warm
medium without nocodazole for 2 to 10 min. At the indicated time-
points in each experiment, the medium was replaced with 0.02%
saponin in order to extract tubulin protomers and the cells were
subsequently subjected to immunoﬂuorescence analysis. Cells were
ﬁxed in 3.7% formaldehyde for 20 min at room temperature and then
incubated in methanol for 20 min at −20 °C. After incubation in
blocking solution (3% BSA, 0.3% Triton X-100) for 30 min, cells were
stainedwith polyclonal anti-γ-tubulin (1:500, Sigma) andmonoclonal
anti-α-tubulin antibody (1:2000, Sigma) for 1 h at room temperature.
Following PBS washes, incubation with secondary antibodies was
performed in the same conditions with Alexa 594-anti-rabbit and
Alexa 488-anti-mouse IgG (Interchim). Samples were washed in PBS
and then counterstained with 500 ng/mL DAPI. Slides were mounted
with ﬂuorescent mounting medium (Dako) and examined using a
ﬂuorescence microscope (Leica DM6000) under the 100× objectivetion on Serine 988 is induced in mitosis-arrested cells. Asynchronous MCF-7 cells were
l extracts were analyzed by Western blotting using anti-pBRCA1 S988 and anti-BRCA1
e 988 following treatmentwith bothmicrotubule-depolymerizing and -stabilizing agents.
hydroxyurea (HU), MCF-7 and HeLa cells were harvested, lysed and subjected to protein
bodies were used to control for gel loading. Cont, whole-cell extracts from untreated
ase onset. After collection by shake-off, mitotic MCF-7 cells were lysed and subjected to
ex was assessed by FACS analysis. Cont, whole-cell extracts from untreated exponentially
s following transfectionwith siRNA directed against BRCA1 or with control siRNA, MCF-7
ted, cell lysateswere treatedwithλ-phosphatase. (F) 24h following transfectionwithHA-
X for 24 h and were then harvested and lysed. 500 μg of cell lysates were used to
as realized with goat anti-pBRCA1 S988 and mouse anti-HA antibodies.
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aster size. We deﬁned a large aster as an aster N10 μm of diameter. The
presented graph reﬂects 3 independent experiments.
2.10. Drug sensitivity assays
Cells were seeded at 104 cells/well in a 96-well microtiter plate,
transfectedwith 100 nM siRNA directed against Chk2 and treated with
various concentrations of paclitaxel 24 h after transfection. 72 h later,
the effects on cell growth were examined by tetrazolium salt WST-1
cleavage assay (Roche). 10 μL of WST-1 were added to each well, and
the cells were incubated for 2 h at 37 °C. Absorbance was measured at
a wavelength of 450 nm. The percentage of cell growth was calculated
by deﬁning the absorbance of cells transfected with siRNA but not
treated with paclitaxel as 100 %. Presented results reﬂect 2
independent experiments performed in octuple. Statistical analysis
was performed with the two-sample Student's t-test using Prism
software (Graphpad Software Inc).
Cell death was evaluated using the trypan blue dye exclusion assay.
48 h or 196 h after treatment with 50 nM paclitaxel, siRNA-transfected
cells were harvested and stained with trypan blue dye. Trypan blue-
positive and -negative cells were counted using a hematocytometer
under a phase-contrast microscope (Nikon ellipse TS100). Results of
each assay were expressed in terms of the percentage of dead cells
relative to the total number of cells. Presented data reﬂect 3
independent experiments performed in duplicate.
3. Results
3.1. BRCA1 is phosphorylated on Ser988 following spindle damage
In normally growing cells, BRCA1 is phosphorylated in a cell cycle
dependent manner, undergoing hyperphosphorylation during the S
phase and being dephosphorylated at the end of mitosis [32,33].
BRCA1 is also hyperphosphorylated following genotoxic stress by DNA
damage-activated kinases such as ATM, ATR and Chk2 [7,9,34]. To date,Fig. 2. BRCA1 phosphorylation on Ser988 in response to spindle damage is Chk2-dependent
downregulation of Chk2. Twenty-four hours following transfectionwith control siRNA (−) or
for 24 h or left untreated (Cont). Cells were harvested, lysed and subjected to immunoblot a
induced BRCA1 phosphorylation on Ser988 in HCT116 cells defective in Chk2. HCT116 cells w
analysis was carried out using anti-pBRCA1 S988, anti-BRCA1 and anti-Chk2 antibodies. (C) C
with 100 nM paclitaxel (PTX) for 24 h or 10 mM hydroxyurea (HU) for 10 h, MCF-7 cells were
T68 and anti-Chk2 antibodies. (D) BRCA1-Chk2 interaction is sensitive to spindle damage. Fo
10 h, MCF-7 cells were harvested and lysed. 500 μg of cell lysates were used to immunoprecip
performed using a non-relevant rabbit IgG fraction (Mock IP). Subsequent immunoblotting w
used for immunoprecipitation is indicated (IP).no study has determined whether BRCA1 is phosphorylated following
other types of stress, such as the one induced by microtubule-
interfering agents. In order to reveal a potential regulation of BRCA1 in
response to spindle damage, we analyzed BRCA1 phosphorylation
upon paclitaxel treatment in MCF-7 cells using commercially available
phospho-Ser-speciﬁc BRCA1 antibodies. Paclitaxel stabilizes micro-
tubules and is widely used in treatment of breast, ovarian and other
solid tumors [35]. It alters the mitotic spindle assembly, leading to
activation of the spindle checkpoint at the metaphase–anaphase
transition and is not reported to induce any DNA-damaging effect. As
shown on Fig. 1A, paclitaxel treatment signiﬁcantly increased BRCA1
phosphorylation on Ser988 in MCF-7 cells, as compared to untreated
exponentially growing cells. This modiﬁcation became obvious on
immunoblot after 6 h of treatment, when 12% of cells were arrested at
prometaphase and continued to increase until 24 h together with the
increasingmitotic index (Fig. 1A). This Ser988-phosphorylated state of
BRCA1 is not speciﬁc to paclitaxel, but is also induced by nocodazole, a
microtubule-depolymerizing agent that disrupts the mitotic spindle
assembly (Fig. 1B). Furthermore, the Ser988-phosphorylation of
BRCA1 following anti-mitotic treatment is visible in both MCF-7 and
HeLa cells (Fig. 1B). The signal of the Ser988-phosphorylated form of
BRCA1 was found to increase by 2–3 fold after spindle damage (Fig.
1B). This phosphorylation level was 1.5 timesmore important than the
one induced by the DNA-damaging agent hydroxyurea (HU) that is
known to activate Chk2, albeit to a lesser extent than IR [36].
Consistent with a previous study [37], our data show that the Ser988-
pBRCA1 form is weakly but clearly detected in untreated asynchro-
nous cells (Fig. 1A and 1B). Since this previous report has revealed a
mitosis-speciﬁc localization of Ser988-phosphorylated BRCA1 in
untreated cells [37], we compared the level of BRCA1 phosphorylation
on Ser988 of untreated M phase-synchronized cells with the one of
untreated asynchronous cells. Our data establish that there is no
difference in the levels of expression of this phosphorylated form of
BRCA1 between the 2 experimental conditions (Fig. 1C), supporting
the ﬁnding that phosphorylation of BRCA1 on Ser988 is induced by
microtubule damage and not by M phase onset.. (A) BRCA1 phosphorylation on serine 988 induced by spindle damage is reduced upon
siRNA directed against Chk2 (+), MCF-7 cells were treated with 100 nM paclitaxel (PTX)
nalysis using anti-pBRCA1 S988, anti-Chk2 and anti-BRCA1 antibodies. (B) Lack of PTX-
ere treated with 100 nM paclitaxel (PTX) for 24 h or left untreated (Cont). Immunoblot
hk2 is phosphorylated on threonine 68 following paclitaxel treatment. After treatment
harvested and lysed. Cell extracts were analyzed byWestern blotting using anti-pCHK2
llowing treatment with 100 nM paclitaxel (PTX) for 24 h or 10 mM hydroxyurea (HU) for
itate BRCA1 using 10 μg of rabbit polyclonal anti-BRCA1. Mock immunoprecipitationwas
as obtained using monoclonal anti-Chk2 and anti-BRCA1 antibodies (IB). The antibody
2227C. Chabalier-Taste et al. / Biochimica et Biophysica Acta 1783 (2008) 2223–2233To ensure target speciﬁcity of the phospho-Ser988 BRCA1 antibody
on Western blot, we checked the expression of the Ser988-
phosphorylated form of BRCA1 using MCF-7 cell extracts obtained
after BRCA1-targeting siRNA incubation (Fig. 1D) or λ-phosphatase
treatment (Fig.1E). Both BRCA1 siRNA transfection and λ-phosphatase
treatment greatly reduced the pBRCA1 Ser988 level by Western
blotting (Fig. 1D, E). In addition, we transfected MCF-7 cells with
pcDNA3 vectors expressing HA-BRCA1wt or HA-BRCA1 with Ser988
mutated to Ala (HA-BRCA1 S988A) proteins (a kind contribution from
Dr JH. Chung) and treated them 24 h later with 100 nM PTX (Fig. 1F).
As expected, immunoprecipitation of a HA-wtBRCA1 protein in PTX-
treatedMCF-7 cells allowed binding of the anti-pSer988 antibody (Fig.Fig. 3. Ser988-phosphorylated BRCA1 accumulates at centrosome in response to spindle d
following nocodazole (NOC) and paclitaxel (PTX) treatment. 24 h after treatment with 100 n
S988 and anti-γ-tubulin antibodies and were examined by ﬂuorescence microscopy. Quanti
cells (n=50). Graphs represent the percentage of ﬂuorescence intensity of centrosomal Ser 98
anti-pBRCA1 S988 antibody. Twenty-four hours following transfection with siRNA directed
S988 and anti-γ-tubulin antibodies and examined under a ﬂuorescence microscope. (C) Spec
subjected to an in situ phosphatase treatment before immunostaining and immunoﬂuoresc1F). In contrast, substitution of S988 by alanine in the immunopre-
cipitated HA-BRCA1 (S988A) protein signiﬁcantly decreased anti-
pSer988 binding, indicating that the antibody was speciﬁc for the
phosphorylated serine residue and did not recognize the S988A
mutant (Fig. 1F). Altogether, our results demonstrate that the antibody
recognizes speciﬁcally BRCA1 phosphorylated on Ser988.
3.2. BRCA1 phosphorylation on Ser988 in response to spindle damage is
Chk2-dependent
Following DNA damage, BRCA1 is phosphorylated by the check-
point kinase Chk2 on serine 988 [9]. To test the hypothesis that Chk2 isamage. (A) Ser988-phosphorylated BRCA1 accumulates at centrosome in mitotic cells
M paclitaxel or 200 ng/mL nocodazole, MCF-7 were immunostained using anti-pBRCA1
ﬁcation of the average ﬂuorescence intensity at centrosome was determined in mitotic
8 pBRCA1 staining in treated as compared to untreated cells. (B) Target speciﬁcity of the
against BRCA1 or control siRNA, MCF-7 cells were immunostained using anti-pBRCA1
iﬁc recognition of phosphorylated BRCA1 by S988 antibody. Untreated MCF-7 cells were
ence analysis.
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response to microtubule damage, we transfected the MCF-7 cells with
established Chk2-targeting siRNA [31] before treatment with
paclitaxel. As previously shown on Fig. 1, the Ser988-phosphorylated
form of BRCA1 increases following PTX treatment when cells have
been transfected with control siRNA (Fig. 2A). In contrast, our data
show that decreased expression of Chk2 following transfection with
Chk2 siRNA results in reduction of phosphorylation of BRCA1 on
Ser988 following spindle damage (Fig. 2A). Although in our experi-
ments the amount of Chk2 could only be reduced by two thirds, this
level of down-regulation was sufﬁcient to decrease PTX-induced
phosphorylation of BRCA1 at Ser988 by 70–80% (Fig. 2A). These results
indicate that phosphorylation on BRCA1 Ser988 in response to spindle
damage is mainly contributed by Chk2. To support these data, we
examined PTX-induced phosphorylation of BRCA1 in human
colorectal cancer cells in which Chk2 had been disrupted through
gene targeting (a kind contribution from Dr B. Vogelstein). Following
exposure to PTX, parental HCT116 Chk2+/+ cells show signiﬁcant
amounts of pBRCA1 S988 as compared to untreated cell (Fig. 2B). In
contrast, PTX-induced phosphorylation of BRCA1 on Ser988 was not
observed in HCT116 Chk2−/− cells (Fig. 2B). These data indicate that
lack of Chk2 expression impairs PTX-induced phosphorylation. Taken
together, our results show that Chk2 is themain kinase responsible for
phosphorylation of BRCA1 on Ser988 following microtubule damage.
On exposure to genotoxic stress, Chk2 becomes fully activated
through a chain of phosphorylations, such as phosphorylation of
Thr68 [38,39]. To further characterize BRCA1 phosphorylation by
Chk2, we next determined if Chk2 could be phosphorylated on Thr68
following microtubule damage. As shown on the immunoblot from
Fig. 2C, Chk2 is efﬁciently phosphorylated on Thr68 after PTX
treatment, as well as following HU treatment, suggesting that spindle
damage induces activation of Chk2. These results are concordant with
recent data showing that nocodazole induces phosphorylation of
Rad53, the Chk2 homolog in S. cerevisiae [40].
The interaction between Chk2 and BRCA1 has been shown to be
sensitive to DNA damage [9]. To further delineate the interaction
between Chk2 and BRCA1 following microtubule damage, we
performed co-immunoprecipitation experiments using cell extracts
from MCF-7 cells treated or not with PTX or HU. In accordance with a
previous study [9], our data indicate that endogenous BRCA1 and Chk2
interact in untreated MCF-7 cells (Fig. 2D). Importantly, BRCA1 is
totally released from Chk2 after paclitaxel treatment, as well as
following DNA damaging treatment (Fig. 2D). These results are
consistent with a model in which the interaction between Chk2 and
BRCA1 is regulated in response to spindle damage. Our ﬁndings
demonstrate that the interaction between Chk2 and BRCA1 is
sensitive to microtubule damage and suggest that PTX-induced
BRCA1 phosphorylation may trigger its release from Chk2, as been
proposed for DNA damage-induced BRCA1 phosphorylation.
3.3. Ser988-phosphorylated BRCA1 accumulates at centrosome in
response to spindle damage
Localization of Ser988-phosphorylatedBRCA1has been shown to be
cell cycle- and DNA damage-dependent [37]. We next studied spindle
damage-induced localization of this phosphorylated form of BRCA1 in
MCF-7 cells. As shown on Fig. 3A, Ser988-phosphorylated BRCA1
staining is diffuse with increased intensity at centrosome in untreated
mitotic cells as well as in cells treated with paclitaxel (PTX) or
nocodazole (NOC). Upon spindle damage however, a larger proportion
of Ser988-phosphorylatedBRCA1 appears to accumulate at centrosome
of prometaphase-arrested cells (Fig. 3A). We then assessed the
accumulation of this centrosomal phosphorylated form of BRCA1 in
untreated mitotic cells and spindle damaged cells by quantifying the
average ﬂuorescence intensity obtained by the phospho-signal
localized at centrosome co-stained by the anti-γ-tubulin antibody.Intensity measurements revealed a signiﬁcant increase (60%; n=50; 3
asterisks, p≤0.001 compared to untreated cells) in the abundance of
centrosomal Ser988 pBRCA1 staining of PTX-treated cells (Fig. 3A).
Similarly, an increase of centrosomal Ser988 pBRCA1 (40%, n=23) was
observed at the centrosome of NOC-treated cells (Fig. 3A). Altogether
our results show that the anti-mitotic treatment triggers a signiﬁcant
accumulation of Ser988-phosphorylated BRCA1 at centrosome inMCF-
7 cells. Similar data were obtained when the Ser988-phosphorylated
BRCA1 accumulation was compared in untreated mitotic versus
microtubule damaged immunostained HeLa cells (data not shown).
To ensure target speciﬁcity of the phospho-Ser988 BRCA1 antibody
in immunoﬂuorescence analysis, we checked the immunostaining
obtained with the anti-Ser988-phosphorylated BRCA1 antibody using
MCF-7 cells following BRCA1-targeting siRNA incubation (Fig. 3B) or
λ-phosphatase treatment (Fig. 3C). Our results demonstrate that the
antibody effectively recognizes a phosphorylated form of BRCA1 by
immunostaining.
3.4. Ser988 is not essential for BRCA1 localization at the centrosome
Post-translational modiﬁcation of BRCA1 on Ser988 upon micro-
tubule damage may modulate its function, association with other
proteins and/or intracellular localization. We investigated whether
Ser988 might be necessary for the subcellular localization of BRCA1 to
the centrosome. For that purpose, we used a phosphorylation mutant
of BRCA1, which contained a serine 988 to alanine substitution
(S988A), thereby abrogating phosphorylation of BRCA1 by Chk2 [9].
Untreated MCF-7 cells were then transiently transfected with pcDNA3
vectors expressing HA-BRCA1wt or HA-BRCA1 S988A proteins. As
shown on the immunoblot Fig. 4A, ectopic over-expression of HA-
BRCA1wt or HA-BRCA1 S988A clearly increased BRCA1 levels inMCF-7
cells compared to the endogenous BRCA1 expression. Calculated by
the percentage of interphase cells showing HA staining, transfection
efﬁciency was about 40% and similar with both vectors. Image stacks
obtained by ﬂuorescence microscopy were collected following co-
staining with anti-γ-tubulin and anti-HA antibodies, to ensure proper
co-localization of exogenous HA-tagged BRCA1 proteins and γ-tubulin
at centrosome. The Fig. 4B illustrates the presence of HA-tagged
BRCA1wt at centrosome. This signal was visible at centrosome in
about 30% of transfected interphase cells. It is noteworthy that none of
the mitotic cells that we examined showed any HA staining under our
experimental conditions. This is probably due to the fact that
overexpression of BRCA1 in MCF-7 cells results in arrest at the G2/M
border [41]. Our data using this exogenously expressed BRCA1 protein
conﬁrmed the endogenous BRCA1 centrosomal localization in
interphase cells [26]. They are not in agreement with results stating
that exogenous EGFP-BRCA1 does not localize to centrosome in
interphase as well as in mitotic cells [42]. Comparing the localization
of HA-tagged BRCA1wt and -BRCA1 S988A proteins, we found that
both are equally recruited at the centrosome in untreated MCF-7 cells
(Fig. 4C). Thus, our data indicate that disrupting the Chk2 phosphory-
lation site does not affect the centrosomal accumulation of BRCA1 in
asynchronous breast cancer cells.
To test whether the effects of the mutation of Ser988 can be
mimicked by the inhibition of Chk2, we next determined the
impact of reduced Chk2 expression on BRCA1 centrosomal
localization. Following transfection with control or Chk2 siRNA,
MCF-7 cells were ﬁxed and co-stained for γ-tubulin and BRCA1. As
shown on Fig. 4D, centrosomal endogenous BRCA1 staining is
detected in both experimental conditions. Centrosomal localization
of BRCA1 was signiﬁcant in 60–70% of cells that were transfected
with Chk2 siRNA (n≥100 cellules per condition). This observation
indicates that the sub-cellular localization of BRCA1 at centrosome
is not dependent on Chk2 and is consistent with our previous
results showing that lack of Ser988 site does not affect BRCA1
centrosomal accumulation.
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BRCA1-dependent ubiquitination activity has recently been shown
to inhibit the microtubule nucleation function of centrosomes [26]. To
further characterize the biological consequences of BRCA1 phosphory-
lation on Ser988 upon spindle damage, we tested whether this
phosphorylation could regulate BRCA1 function in controlling micro-
tubule nucleation. The human breast cancer cell line HCC1937 carries
a BRCA1-null mutation and the 5382insC allele, producing a slightly
truncated protein that contains an immature BRCT domain and is
expressed at a lower level compared to that in cells with wild-type
BRCA1 such as MCF-7 and HeLa [30]. We used a microtubule regrowthFig. 4. Ser988 is not essential for BRCA1 localization to the centrosome. (A) Transient over-ex
Twenty-four hours after transfection with pcDNA3 vectors encoding HA-tagged BRCA1wt an
blot analysis using anti-BRCA1 and anti-HSP60 antibodies. (B) Centrosomal localization
immunostained using anti-HA and anti-γ-tubulin antibodies and examined under a ﬂuores
images. Figure shows 6 on 11 captured images. (C) Phosphorylation of Ser988 is not essenti
pcDNA3 vectors encoding HA-tagged BRCA1wt and HA-tagged BRCA1 S988A, MCF-7 cells w
ﬂuorescence microscope. Centrosomal localization of HA-BRCA1 was determined by scorin
centrosome is not dependent on Chk2. 24 h after transfectionwith control siRNA or Chk2 siRN
γ-tubulin antibodies and examined under a ﬂuorescence microscope. Localization of BRCA1assay on these cells that were transiently transfected by a control
vector or a vector expressing HA-BRCA1wt or HA-BRCA1 S988A (Fig.
5A). The steady-state level of HA-BRCA1wt in HCC1937 cells was
approximately 3–4 fold higher than that of the truncated product (Fig.
5A). As already shown by Okada and Ouchi [37] and as previously
observed in Figs. 1 and 2, Ser988 pBRCA1 is weakly detected in
untreated cells, in absence of any exogenous damage (Fig. 5A). This
basal BRCA1 phosphorylation is obvious under conditions of HA-
BRCA1wt overexpression (Fig. 5A). Next, cells were treated with
nocodazole for 1 h in chilled medium to depolymerize microtubules.
Centrosomes initiated re-nucleation when fresh prewarmed medium
without nocodazole was added back. Cells were then ﬁxed at variouspression of HA-tagged BRCA1wt and HA-tagged BRCA1 S988A in untreated MCF-7 cells.
d HA-tagged BRCA1 S988A, MCF-7 cells were harvested, lysed and subjected to Western
of HA-tagged BRCA1wt. Twenty-four hours after transfection, MCF-7 cells were
cence microscope. Localization of HA staining at centrosome was performed on z-stack
al for BRCA1 localization at the centrosome. Twenty-four hours after transfection with
ere immunostained using anti-HA and anti-γ-tubulin antibodies and examined under a
g n≥150 transfectants from 3 independent experiments. (D) BRCA1 localization at the
A, MCF-7 cells were immunostained using monoclonal anti-BRCA1 and polyclonal anti-
at centrosome was assessed in n≥100 cells per condition.
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asters, as illustrated on representative images of the different aster
morphologies on Fig. 5B. Only large asters showing a signiﬁcant
number of microtubules N10 μMdiameter were scored for subsequent
quantiﬁcation (Fig. 5B). As indicated on Fig. 5C, cells transfected with
HA-BRCA1wt showed a strong reduction in microtubule nucleation
compared to the control cells, 2 and 4 min after initiation of
repolymerization, consistent with BRCA1 inhibiting the microtubule
nucleation function of centrosome. In contrast, cells transfected with
HA-BRCA1 S988A did not show reduction in microtubule nucleation
compared to cells expressing wtBRCA1 (asterisk, p≤0.05 compared
with wtBRCA1; 2 asterisks, p≤0.01 compared with wtBRCA1) (Fig. 5C).
These results were obtained on microtubule nucleation activity
observed from interphasic as well as from mitotic centrosomes.
Thus, our ﬁndings strongly suggest that Ser988 is important for BRCA1
function in microtubule nucleation.
3.6. Ser988 is important for BRCA1 function in cell survival following
spindle damage
To further examine the biological signiﬁcance of our data, we next
determined whether phosphorylation of BRCA1 on Ser988 has a
consequence on BRCA1 function in cell survival following spindleFig. 5. Ser988 is important for BRCA1 function in microtubule nucleation. (A) Transient ov
Twenty-four hours after transfection with pcDNA3 vectors, HCC1937 cells were harvested, ly
anti-pBRCA1 S988 antibodies. (B) Representative ﬁelds of the three different aster morpholog
images were reproduced at the same magniﬁcation. (C) BRCA1 effect on centrosomal microt
after transfection with pcDNA3 vectors, a microtubule nucleation assay was set up in HCC193
percentage of large asters scored from three independent experiments. Asterisk, p≤0.05 codamage. It was shown that BRCA1 deﬁciency confers resistance to
anti-microtubule agents, such as paclitaxel and Vinorelbine [14–17],
HCC1937 breast cancer cells, which carry a homozygote mutation in
BRCA1 are signiﬁcantly less sensitive to paclitaxel compared with
MCF-7 cells that express awild-type BRCA1 protein [14]. Expression of
a full-length BRCA1 cDNA restored the sensitivity to PTX in transfected
HCC1937 cells compared to parental cells [14]. We then compared
wild-type BRCA1 and BRCA1 S988A for their ability to sensitize
HCC1937 cells to PTX. 24 h after transfection with empty pcDNA3
vector, HA-wtBRCA1 or HA-BRCA1 S988A vectors, HCC1937 cells were
treated with 50 nM PTX for 48 h. Cell mortality was assessed scoring
the number of dead cells using the trypan blue exclusion assay. As
shown on Fig. 6A, the percentage of dead cells 48 h after PTX
treatment was signiﬁcantly lower in cells lacking BRCA1 (empty
pcDNA3) or expressing a mutated BRCA1 (S988A) protein compared to
cells expressing a wtBRCA1 protein (Asterisk, p≤0.05 compared with
wtBRCA1; two asterisks, p≤0.01 compared with wtBRCA1). Similar
results were obtained 7 days after PTX treatment (Fig. 6A). These data
strongly suggest that phosphorylation of Ser988 is important for
BRCA1 function in cell survival following spindle damage.
Since our ﬁndings indicated that presence of Ser988 had an
impact on cell sensitivity to PTX and that Chk2 is the main kinase
responsible for phosphorylating BRCA1 on this site, we nexter-expression of HA-tagged BRCA1wt and HA-tagged BRCA1 S988A in HCC1937 cells.
sed and subjected to Western blot analysis using anti-BRCA1, anti-HA, anti-HSP60 and
ies scored in the in cellulo microtubule regrowth assay established in HCC1937 cells. All
ubule nucleation is abolished by mutation of the serine 988 residue. Twenty-four hours
7 cells as described in “Materials and methods”. Histograms showmean values±SEM of
mpared with wtBRCA1; 2 asterisks, p≤0.01 compared with wtBRCA1.
Fig. 6. Expression of a non-phosphorylatable BRCA1 S988A mutant or down-regulation
of Chk2 render breast cancer cells less sensitive to paclitaxel. (A) Decreased paclitaxel-
induced cell death upon expression of a non-phosphorylatable BRCA1 S988A mutant.
24 h following transfection with HA-wtBRCA1 or HA-BRCA1 S988A plasmids, HCC1937
cells were treated with 50 nM PTX for 48 h or 7 days. Cell viability was assessed using
trypan blue exclusion assay. The histograms show mean values±SEM from 3
independent experiments in duplicate. Asterisk, p≤0.05 compared with HCC1937
cells transfected with HA-wtBRCA1; two asterisks, p≤0.01 compared with HCC1937
cells transfected with HA-wtBRCA1. (B) Decreased paclitaxel sensitivity upon down-
regulation of Chk2. 24 h following transfection with siRNA, MCF-7 cells were treated
with PTX at various concentrations. Cell growthwas assessed 72 h after spindle damage
treatment using WST-1 assay. The graphs show mean values±SEM from 2 independent
experiments in octuple. 3 asterisks, p≤0.001 compared with MCF-7 cells transfected
with control siRNA.
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sensitivity to anti-mitotic treatment. Cell survival was assessed 72 h
following PTX exposure by using the cell proliferation WST-1 assay.
As shown on Fig. 6B, MCF-7 cells transfected with Chk2 siRNA were
signiﬁcantly less sensitive to PTX than were control cells. Down-
regulation of Chk2 increased paclitaxel resistance by 4-fold in MCF-7
cells with an observed IC25 from 5 nM to 20 nM (3 asterisks,
p≤0.001 compared with control siRNA). These data are consistent
with our results showing that expression of a non-phosphorylatable
BRCA1 mutant by Chk2 decreases cell sensitivity to microtubule
damaging treatment. Therefore, cells expressing BRCA1 mutant
S988A behave like Chk2-deﬁcient cells in terms of PTX sensitivity.
Our ﬁndings suggest that BRCA1-mediated role in cell survival
following microtubule-damaging treatment requires phosphoryla-
tion of BRCA1 on Ser988 by Chk2.
4. Discussion
Aside from its essential functions in the DNA damage response
BRCA1 has been also involved in the cellular response to microtubule
damage. In this study, we have shown for the ﬁrst time that BRCA1 is
phosphorylated on Ser988 by Chk2 upon anti-mitotic treatment. In
addition, we demonstrated that BRCA1 functions in inhibiting
microtubule nucleation of centrosome and in regulating cell survival
following microtubule damage in breast cancer cells are dependent
upon the presence of the Ser988 residue in BRCA1.4.1. BRCA1 phosphorylation on Ser988 upon microtubule damage is
Chk2-dependent
Our results have established that spindle damage induced by anti-
mitotic drugs that stabilize or depolymerize microtubules induces the
phosphorylation of the Ser988 residue of BRCA1. This novel ﬁnding
was consistent in breast cancer MCF-7 cells as well as in cervical
carcinoma HeLa cells. In addition, we provide evidence that
phosphorylation of BRCA1 on Ser988 is induced by microtubule
damage and not by M phase onset, suggesting that sustained
activation of the spindle checkpoint is required to induce BRCA1
phosphorylation.
Our data clearly showed that BRCA1 phosphorylation on Ser988
following microtubule damage is Chk2-dependent. It is known that
Thr68-phosphorylation is required for full activation of Chk2,
probably because it promotes the oligomerization of the checkpoint
kinase [38,39,43]. We found that Chk2 is phosphorylated on Thr68
after spindle damage, strongly suggesting that Chk2 is activated
following treatment withmicrotubule-interfering agents. This implies
that Chk2may be activated by a large variety of signals monitoring cell
cycle progression, including mitotic surveillance. Our ﬁndings suggest
a novel potential involvement of Chk2 in the spindle damage response
in mammalian cells. They are consistent with a recent study showing
that activation of the spindle assembly checkpoint by nocodazole
induces changes in Rad53 (the Chk2 homolog in S. cerevisiae)
phosphorylation state, implicating Rad53 in the spindle damage
response [40]. Furthermore, a role in spindle checkpoint signaling has
been recently described for Chk1, another mammalian key effector of
the DNA damage response [44] and studies have suggested that the
spindle assembly checkpoint is involved in regulation of DNA damage
responses in mammalian cells [45,46]. Altogether, these data imply
connections between DNA damage and spindle damage responses.
Chk2 activation by phosphorylation following DNA damage is
dependent of ATM and ATR, members of the phosphatidylinositol 3-
kinase family [7,39]. ATM is speciﬁcally activated by IR and other
sources of DSBs, whereas ATR is suggested to function in parallel with
ATM in response to stalled replication forks resulting from HU or UV
treatment. Our results raise the question of what kinase(s) could
phosphorylate Chk2 on Thr68 following spindle damage. Several
kinases displaying maximum activity during M phase could function
upstream from Chk2. Polo-like kinase1 (Plk1) is a serine/threonine
protein kinase that has been associated with many aspects of mitosis
and accumulates to maximal levels during G2 and M phases [47]. TTK/
hMps1 is a also a serine/threonine protein kinase that is required for
the spindle assembly checkpoint and displays maximal activity during
M phase [48]. Since both Plk1 and TTK/hMps1 kinases can phosphor-
ylate Chk2 in vitro on Thr68 [49,50], it is tempting to speculate that
one and/or the other could mediate Chk2 phosphorylation upon
spindle damage.
4.2. Phosphorylated S988 BRCA1 accumulates at centrosome following
spindle damage
Approaches using anti-BRCA1 antibodies demonstrated centroso-
mal localization of BRCA1 by indirect immunoﬂuorescence throughout
the cell cycle [26,28,51]. However, a recent study using EGFP-tagged
fusion BRCA1 protein has questioned these data and presented
evidence that BRCA1 is not a centrosomal protein [42]. To ensure
accurate localization of BRCA1, we have analyzed the sub-cellular
localization of an exogenous HA-tagged BRCA1wt protein. Our results
showed reliable co-localization of BRCA1with centrosomalγ-tubulin in
interphase cells, reinforcing BRCA1 association with centrosome.
It is well known that phosphorylation of speciﬁc residues of BRCA1
affects its subcellular localization. Localization of Ser988-phosphory-
lated BRCA1 has been shown to be cell cycle- and DNA damage-
dependent [37]. Our data indicate that Ser988-phosphorylated BRCA1
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treated with microtubule-damaging agents. We found that the anti-
mitotic treatment does not disrupt Ser988-phosphorylated BRCA1
association with the centrosome but triggers a signiﬁcant accumula-
tion of this phosphorylated form to centrosome. This may reﬂect
direct regulation of centrosomal BRCA1 by Chk2, as it was reported
that Thr68 phosphorylated Chk2 is localized to centrosome in the
absence of DNA damage [49]. In support of this, we found that
recruitment of BRCA1 to centrosomes is not dependent of the
presence of its Ser988 phosphorylatable site, nor dependent of the
expression of Chk2. It is then tempting to speculate that the
accumulation of Ser988-phosphorylated BRCA1 that we observed at
centrosome upon spindle damage is due to an increase in the
phosphorylation of centrosomal BRCA1 by Chk2 in close proximity.
4.3. Ser988 is important for BRCA1 microtubule nucleation-inhibiting
activity and for BRCA1 function in cell survival following
microtubule damage
To further characterize the biological consequences of BRCA1
phosphorylation on Ser988 upon spindle damage, we tested whether
this phosphorylation could regulate one of BRCA1 functions. So far, the
most common approach to determine how BRCA1 phosphorylations
can contribute to some pathway was to evaluate the consequences of
the re-expression of wild-type or phospho-deﬁcient forms of BRCA1
in BRCA1-null cells such as the breast cancer HCC1937 cells. Using this
approach, it was recently shown that prevention of Chk2-mediated
phosphorylation via mutation of the serine 988 residue of BRCA1
disrupted both the BRCA1-dependent promotion of HR and the
suppression of NHEJ following DSBs induction [10]. Since BRCA1 has
recently been shown to inhibit the microtubule nucleation function of
centrosomes [26], we then studied the consequences of disrupting
BRCA1 phosphorylation on residue serine 988 on this BRCA1 activity
following microtubule depolymerization. We found that mutation of
the serine 988 abolished the inhibition of microtubule nucleation
activity of BRCA1. Our study clearly indicates that Ser988 is important
for BRCA1 function in microtubule nucleation. It is known that this
function is dependent upon ubiquitination of γ-tubulin by the E3
ubiquitin ligase activity associated with the BRCA1/BARD1 complex
[26]. Thus, our ﬁndings suggest that BRCA1-mediated ubiquitination
could be regulated by phosphorylation of speciﬁc residues of the
protein, such as the serine 988. Consistent with this idea, a recent
report has shown that the BRCA1/BARD1 ubiquitin ligase activity is
down-regulated by CDK2/cyclin E, suggesting a cell cycle control of
this BRCA1 activity [52].
It has been previously reported that phosphorylation of BRCA1 at
serine 988 is essential for the ability of wtBRCA1 to restore survival
after DNA damage in the BRCA1-mutated cell line HCC1937 [9]. Our
ﬁndings show that the serine 988 site is also required for BRCA1
function in cell survival following PTX treatment. This notion is
substantiated by our siRNA experiments showing that knockdown of
Chk2 has similar effects on PTX survival that the expression of a non-
phosphorylatable S988A BRCA1 mutant. The actual regulatory
pathway involving pBRCA1 Ser988 in cell survival to microtubule-
interfering agents awaits further investigation.
In summary, our data provide evidence for post-translational
modiﬁcation of BRCA1 on serine 988 by the checkpoint kinase Chk2
that is activated following spindle damage. In addition, we report
that the Ser988 site is important for the centrosomal microtubule
nucleation-inhibiting activity of BRCA1 and for BRCA1 function in
survival following microtubule damage. This novel regulation
suggests a ﬁne cross-talk between DNA damage and spindle
damage responses. Microtubule inhibitors are potent therapeutic
drugs for cancer treatment. These drugs lead cells to mitotic arrest
due to inhibition of a proper mitotic spindle assembly. BRCA1 and
Chk2 are new members of the spindle damage response. Germlinemutations and down-regulation of BRCA1 have been associated
with paclitaxel resistance in breast cancer cells. Understanding
BRCA1 and Chk2 regulations and functions during mitotic arrest
may provide interesting prospects for improving cancer treatment
and knowing their status may predict anti-mitotic treatment
efﬁciency.
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